Normal ranges for PSA, PSA density, and MRI-assessed prostate volume in healthy males from Germany

Overview

This study establishes normative reference values for prostate-specific antigen (PSA), MRI-derived prostate volume (PV), and PSA density (PSAD) in a healthy male population from Germany.

Background

Prostate-specific antigen (PSA), prostate volume (PV), and PSA density (PSAD) are crucial biomarkers in assessing prostatic diseases. Accurate reference values are essential for effective risk stratification and clinical decision-making. Current literature indicates that traditional reference values may not adequately reflect physiological variations.

Data Highlights

The source material does not provide specific numerical reference values or details about the study cohort. It describes the study as establishing reference values for PSA, MRI-derived PV, and PSAD in healthy males from Germany.

Key Findings

• PSA, PV, and PSAD are important biomarkers for assessing prostatic diseases.

• Reference values for PV have historically relied on transrectal ultrasound, which may underestimate PV compared to MRI.

• Age-adjusted values for PSA are recommended to account for physiological variability.

• Generalized additive models for location, scale, and shape (GAMLSS) are suggested for more accurate modeling of PV and PSA-related measures.

• The study cohort was derived from a population-based initiative.

Clinical Implications

The establishment of normative values for PSA, PV, and PSAD can aid clinicians in understanding prostate health metrics.

Conclusion

This study provides reference values for PSA, PV, and PSAD in healthy males.

Related Resources & Content

1. European Radiology, 2025 -- Influence of Prostate Size and PI-RADS Classification on PSA Density Thresholds for Biopsy Decision-Making

2. Assessing the Likelihood of Clinically Relevant Prostate Cancer After Suspicious mpMRI Findings: Insights from a High-Volume Medical Center, 2024

3. Frontiers in Oncology, 2026 -- Incremental diagnostic value of MRI PI-RADS classification combined with PSA density for prostate cancer

4. The ASCO Post, 2024 -- Benefit of Prostate MRI Plus PSA Density Test in Patients Suspected of Having Prostate Cancer

5. Diagnostic Evaluation - EAU Guidelines on Prostate Cancer, 2026

6. Primary Noncontrast Magnetic Resonance Imaging for Prostate Cancer Screening: A Randomized Clinical Trial (PROSA) - PubMed, 2026

7. To biopsy or not biopsy, that is the question - PI-RADS 3 prostate lesions - validation of clinical and radiological parameters for biopsy decision-making - PubMed, 2026

8. Diagnostic Evaluation - EAU Guidelines on Prostate Cancer - Uroweb

9. Primary Noncontrast Magnetic Resonance Imaging for Prostate Cancer Screening: A Randomized Clinical Trial (PROSA) - PubMed

10. To biopsy or not biopsy, that is the question - PI-RADS 3 prostate lesions - validation of clinical and radiological parameters for biopsy decision-making - PubMed